The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC).
Dana E. Rathkopf
Research Funding - Aragon Pharmaceuticals
Emmanuel S. Antonarakis
Research Funding - Aragon Pharmaceuticals
Neal D. Shore
No relevant relationships to disclose
Ronald Tutrone
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Charles J. Ryan
No relevant relationships to disclose
Mansoor N. Saleh
No relevant relationships to disclose
Ralph J. Hauke
No relevant relationships to disclose
Edna Chow Maneval
Employment or Leadership Position - Aragon Pharmaceuticals
Stock Ownership - Aragon Pharmaceuticals
Howard I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U)
Research Funding - Aragon Pharmaceuticals